BMS-345541 | 445430-59-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: BMS-345541
• 英文别名: 1,2-Ethanediamine, N-(1,8-dimethylimidazo(1,2-a)quinoxalin-4-yl)-, monohydrochloride；N'-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine;hydrochloride
• CAS: 445430-59-1
• 化学式: C₁₄H₁₇N₅*ClH
• 分子量: 291.783
• InChiKey: MIDKPVLYXNLFGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.29
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  68.2
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  BMS-345541 、 (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycine 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以52 %的产率得到N-(2-((1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)amino)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide
  参考文献：
  名称：

  METHODS AND MATERIALS FOR TREATING CANCER

  摘要：

  This document relates to methods and materials involved in treating a mammal (e.g., a human) having cancer. For example, bifunctional molecules (e.g., protein targeting chimeras (PROTACs)) that include (a) a targeting moiety that binds to a MET polypeptide, (b) a linker, and (c) an E3 ligase ligand are provided. In some cases, a bifunctional molecule (e.g., a PROTAC targeting a MET polypeptide) provided herein can be administered to a mammal having cancer (e.g., a cancer including one or more cancer cells having an oncogenic MET polypeptide such as a MET polypeptide lacking at least a portion of the amino acid sequence encoded by exon 14) to treat the mammal.

  公开号：

  WO2023249994A1
• 作为产物：
  描述：

  N1-?(1,?8-?二甲基咪唑并[1,?2-?a]?喹噁啉-?4-?基)?-1,?2-?乙二胺 在 盐酸 作用下， 以 水 为溶剂， 生成 BMS-345541
  参考文献：
  名称：

  Imidazoquinoxaline compound for the treatment of melanoma

  摘要：

  本发明涉及一种（4（2'-氨基乙基）氨基-1,8-二甲基咪唑并（1,2-a）喹喔啉）-4,5-二氢-1,8-二甲基咪唑并（1,2-a）喹喔啉-4-酮-2-羧酸（BMS-345541）或其类似物，用于治疗黑色素瘤癌。该化合物抑制NFκB活性和表达，并在黑色素瘤癌细胞中诱导凋亡。本发明还提供了一种用于检测抑制黑色素瘤癌细胞生长的方法。

  公开号：

  US20060025419A1

文献信息

• Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
  申请人：Sanofi-Aventis

  公开号：EP2532755A1

  公开（公告）日：2012-12-12

  A method of detecting the effect of a compound on a pain-related tissue status or a pain-related disease, uses of Slfn2, uses of a cell overexpressing Slfn2 or of a Slfn2 knock-out cell, methods for determining a pain-modulating effect of a compound, a method for determining or adapting the dosage of a compound for the prevention or treatment of a pain-related tissue status or disease, a method of determining the beneficial or adverse effect of a substance, a kit for detecting the effect of a compound on a pain-related tissue status or disease, a compound able to lower Slfn2 activity for use in the prevention or treatment of a pain-related tissue status or disease and a method of preventing or treating a pain-related tissue status or disease.

  一种检测化合物对与疼痛有关的组织状态或与疼痛有关的疾病的影响的方法，Slfn2的用途，过表达Slfn2的细胞或Slfn2敲除细胞的用途，确定化合物的疼痛调节作用的方法，确定或调整用于预防或治疗与疼痛有关的组织状态或疾病的化合物的剂量的方法、一种确定物质的有益或有害影响的方法，一种检测化合物对疼痛相关组织状态或疾病的影响的试剂盒，一种用于预防或治疗疼痛相关组织状态或疾病的能够降低Slfn2活性的化合物，以及一种预防或治疗疼痛相关组织状态或疾病的方法。
• Method of treating glioma
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US10377818B2

  公开（公告）日：2019-08-13

  Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (BDNF), or brevican, to a patient with a glioma. In certain embodiments, the subject methods involve treating a neurological dysfunction, reducing invasion of a glioma cell into brain tissue, and/or reducing the growth rate of a glioma in the patient. Also provided herein are methods for identifying an agent that modulates the mitotic index of a glial cell, and methods for stimulating the proliferation of a glial cell. Kits that find use in practicing the subject methods are also provided.

  本发明提供了治疗胶质瘤的方法。本发明的方面包括向胶质瘤患者施用治疗有效量的抑制选自神经ligin-3、脑源性神经营养因子（BDNF）或brevican的一种或多种神经元活性调节蛋白活性的制剂。在某些实施方案中，该主题方法涉及治疗神经功能障碍、减少胶质瘤细胞对脑组织的侵袭和/或降低患者体内胶质瘤的生长速度。本文还提供了鉴定调节胶质细胞有丝分裂指数的药剂的方法，以及刺激胶质细胞增殖的方法。还提供了可用于实施上述方法的试剂盒。
• COMPOSITIONS AND METHODS FOR INHIBITING NF- kB AND SOD-1 TO TREAT AMYOTROPHIC LATERAL SCLEROSIS
  申请人：The Research Institute at Nationwide Children's Hospital

  公开号：EP3065784A1

  公开（公告）日：2016-09-14
• Methods for Inhibiting Prostate Cancer
  申请人：Karin Michael

  公开号：US20140086918A1

  公开（公告）日：2014-03-27

  The invention provides methods for reducing growth and/or metastasis of androgen-independent (castration resistant) prostate cancer in a tissue in an animal. In one embodiment the method comprises administering to the animal a therapeutically effective amount of a compound that reduces the number of B cells, and/or the function of B cells, in the tissue. In yet another embodiment, the invention provides methods for reducing androgen-induced growth of prostate epithelial cells in prostate tissue in an animal. In one embodiment, the method comprises administering to the animal a therapeutically effective amount of a compound that reduces the number of B cells, and/or the function of B cells, in the tissue.
• Method of Treating Glioma
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20160222100A1

  公开（公告）日：2016-08-04

  Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (BDNF), or brevican, to a patient with a glioma. In certain embodiments, the subject methods involve treating a neurological dysfunction, reducing invasion of a glioma cell into brain tissue, and/or reducing the growth rate of a glioma in the patient. Also provided herein are methods for identifying an agent that modulates the mitotic index of a glial cell, and methods for stimulating the proliferation of a glial cell. Kits that find use in practicing the subject methods are also provided.